Introduction {#sec1-1}
============

Breast cancer is the most frequent malignancy in women and the leading cause of death among this population.^[@ref1]^ The estimated number of new cases of breast cancer in Brazil in 2014 is 57,120, with an estimated risk of 57.09 cases per 100,000 women.^[@ref1]^ Gastric metastasis is rare and few cases have been described. Breast cancer is the second most frequent malignancy which presents with gastric metastasis, surpassed only by melanoma.^[@ref2],[@ref3]^ The most frequent sites of breast cancer metastasis are local and distant lymph nodes, brain, lungs, liver, and bones.

It has been described by Ciulla and colleagues that 6% of women with breast cancer develop gastric metastasis during the course of the disease.^[@ref2]^ Symptoms of gastric metastasis are often nonspecific and can be confused with side effects of the cancer treatment.^[@ref4]^ Diagnosis is established after performing biopsy through endoscopy followed by histological and immunohistochemical analysis. It can be difficult to differentiate primary gastric cancer from gastric metastasis. Women with breast cancer metastatic to the stomach have a worse prognosis and higher chance of disease progression to other sites. According to a Dutch case series, patients in this situation had median overall survival of two years. Only 22% of the patients survived more than two years.^[@ref4]^ The aim of treatment is palliative and includes chemotherapy alone or combined with biologic agents, hormone therapy, and radiation therapy. Surgery is indicated in selected cases when perforation, massive bleeding or obstruction occurs. Nevertheless, surgery has low impact on survival.^[@ref4]^

Four breast cancer patients with gastric metastasis were reported.

Case Report {#sec1-2}
===========

Four patients with breast cancer metastatic to the stomach have been identified. The mean age at diagnosis of cancer was 56 years old (ranging from 47 to 67 years old). The average age at diagnosis of gastric metastasis was 61.5 years (ranging from 51 to 74 years old). The patients' characteristics are listed in [Table 1](#table001){ref-type="table"}.

Patients 1 and 2 had invasive lobular carcinoma and patients 3 and 4 had invasive ductal carcinoma. The mean time between the diagnosis of the disease and the presentation of gastric metastasis was 57 months (ranging from 38 to 76 months). Non-specific symptoms such as epigastric pain, dyspepsia and vomiting were reported. Patients 1 had estrogen receptor 100%, progesterone receptor 100%, Ki 67 10% and human epidermic growth factor 2 (HER-2) negative on the immunohistochemistry of the primary lesion and gastric metastasis. Patients 2 had estrogen receptor 100%, progesterone receptor 100%, Ki 67 60% and HER-2 negative on the immunohistochemistry of the primary lesion and gastric metastasis. Patients 3 had estrogen receptor 100%, progesterone receptor 100%, Ki 67 30% and HER-2 negative on the immunohistochemistry of the primary lesion and gastric metastasis. Patient 4 had estrogen receptor 100%, progesterone receptor 100%, Ki 67 25% and HER-2 inconclusive on the primary lesion and estrogen receptor 95%, progesterone receptor 45% and HER-2 negative on the gastric metastasis. [Figure 1](#fig001){ref-type="fig"} demonstrates histological samples stained by hematoxylin and eosin in patient 1. Endoscopic findings were ulcerated lesion on patient 1; diffuse infiltration (linitis) on patient 2; infiltrative, ulcerated, stenotic lesion in distal antrum and pylorus on patient 3; and flat erosion lesions on patient 4. Patient 1 underwent total gastrectomy due to major bleeding; patient 2 and 4 received chemoradiotherapy to local control and patient 3 received chemotherapy only. Although the development of gastric metastasis means poor prognosis, patient 1 survived for eight years after the diagnosis of gastric metastasis

Of the 4 patients, 2 died of metastatic disease in multiple organs; 1 died 13 months after the diagnosis and the other died 103 months after diagnosis. It is worth noting that the patient who had the longest survival rate presented gastric disease as her only disease site, and was initially treated with surgery. In our evaluation of clinical variables, the most notable feature was the incidence of meningeal disease, which was symptomatic in patients 1, 2 and 4 and was the cause of death of patients 1 and 2.

Discussion {#sec1-3}
==========

The majority of breast tumors arise in the ductal epithelium. The lobular subtype represents the second most frequent breast neoplasia.^[@ref1]^ Metastatic dissemination to the upper gastrointestinal tract is related mainly to lobular infiltrative breast carcinoma.^[@ref2],[@ref3]^ In this series, half of the patients had lobular carcinoma according to the finding of Pectasides and colleagues series, in which 5 of 8 patients had the lobular subtype. In a series published by Taal and colleagues, 83% of the 51 patients with gastric metastasis had a lobular subtype.^[@ref4],[@ref5]^ Since de the ductal subtype is the most common breast neoplasm, the proportion of our series seems reasonable.

Endoscopic findings varied, which is consistent with the literature. Gastric metastasis can be presented with benign characteristics, diffuse infiltrations, nodules and/or ulcerations.^[@ref6]^ The most common presentation is plastic linitis with diffuse infiltration to the submucosa and muscularis propria.^[@ref5]^ The lesions are usually present in the fundus and gastric body, which can be isolated.^[@ref6]^

Since gastric cancer and gastric metastasis of breast cancer present with practically the same clinical, endoscopic and radiological characteristics,^[@ref7]^ the immunohistochemical profile is the most reliable method to distinguish them and therefore establish diagnosis. Often, the markers cytokeratin (CK) 7, CK19, carcinoembryonic antigen (CEA), estrogen receptor (RE), and progesterone receptor (RP) are present in breast cancer metastasis. The intense positivity of the RE and RP allows the definite diagnosis of gastric metastasis of breast cancer.^[@ref6]^ The estrogen receptor is an important biomarker since its positivity predicts the response to hormonal therapy, which means a better prognosis. The presence of the progesterone receptor is intimately related to the estrogen receptor, and isolated expression of the RP is rare (1% of the breast cancer cases). The best response to endocrine therapy occurs when both are present.

The overexpression of the HER-2 is related to greater tumor proliferation, since it codes one of the tumor cell protein that accelerates cellular proliferation. CK7 is present in 90% of breast cancer and 50 to 64% of primary gastric cancer. In our series, none of the patients overexpressed HER-2. CEA is usually found in gastrointestinal and breast neoplasms. However, it can be present in both benign and malignant cases.^[@ref8]^ Patients 1 and 2 had expression of CEA in immunohistochemistry.

The patients presented with epigastric pain, dyspepsia, bloating, and vomiting, compatible with upper gastrointestinal disease. The non-specificity of symptoms can be misunderstood with adverse effects of treatment, leading to a delay in diagnosis, which invariably has a negative impact on patient survival. This fact is supported by autopsy data, which show gastric metastases in 18% of patients, while only 6% of patients received diagnosis during life.^[@ref4]^ The mean time between breast cancer diagnosis and its progression to gastric metastasis was 31.5 months (ranging from 10 to 53 months). In a Dutch trial, the mean time to progression was 27 months (ranging from 0 to 176 months). In another series published by Pectasides and colleagues, the mean time to progression was 41 months (ranging from 2 to 82 months). Systemic therapy is indicated for gastric metastasis from breast cancer and it can involve chemotherapy, radiation therapy or hormone therapy, alone or in combination. Surgery is reserved for selected cases, mostly when complications such as perforations, hemorrhage or obstruction occur. To treat obstructions, an endoluminal stent can be indicated. When bleeding occurs, endoscopic or endovascular therapy is suggested. Surgical treatment has no impact on global survival according to various published studies.^[@ref4],[@ref5],[@ref9]^

Systemic therapy with chemotherapy is also routinely used in these situations.^[@ref9]^ RE-positive gastric metastases have shown a good response to hormonal therapy and chemotherapy with significant increase of overall survival.^[@ref2]^ Patients with invasive lobular carcinoma usually have good response to hormone therapy.^[@ref9]^ In this series, all patients received chemotherapy as first line treatment. One of the patients received hormone therapy in second line treatment. Only one patient received radiation therapy combined with chemotherapy as an upfront treatment. Another one underwent radiation therapy after failure of the first line. A patient that had isolated gastric metastasis underwent total gastrectomy. In patients with breast cancer, the finding of a gastric lesion may represent metastasis instead of a second malignancy. The incidence of leptomeningeal carcinomatosis varies from 3 to 8% of solid tumors. The most common causes of leptomeningeal carcinomatosis are breast cancer, lung cancer and malignant melanoma.^[@ref10]^ In our series, three patients had meningeal infiltration, so we hypothesized that there could be some similarity between meningeal and gastric tumor microenvironment favorable to tumor cell implantation

Conclusions {#sec1-4}
===========

Although rare, gastric metastasis can have a negative impact on survival, and must be investigated in patients with breast cancer who present with dyspepsia and other upper gastrointestinal symptoms. Diagnostic confirmation involves comparison of the histology of the primary tumor and the metastasis, with immunohistochemistry as an essential tool. In this context, the treatment should be individualized and comprise local or systemic therapy, depending on the progression of the disease. Since survival rates constantly increase with the development of new treatments, one must pay attention to metastasis occurring in sites where it was previously unusual.^[@ref5],[@ref11]^ The presentation as a single metastasis favors a more positive prognosis. The association with meningeal dissemination suggests that there is some biological similarity between these types of lining epithelium that favors the implantation of tumor cells via hematogeneous pathway.

![Histological sample stained by hematoxylin and eosin of patient 1.](rt-2016-3-6305-g001){#fig001}
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Patients' characteristics.

                                   Patient 1                               Patient 2                               Patient 3                                                                   Patient 4
  -------------------------------- --------------------------------------- --------------------------------------- --------------------------------------------------------------------------- -------------------------------------------
  Date of birth                    07 Jun 1949                             20 Oct 1961                             15 Jul 1947                                                                 31 Jul 1939
  Date of diagnosis                May 1999                                Aug 2009                                May 2009                                                                    Jan 2007
  Type of tumor                    Lobular invasive                        Lobular invasive                        Ductal invasive                                                             Ductal invasive
  First line treatment             Carboplatin + Docetaxel                 Capecitabine e Radiotherapy             Docetaxel + Capecitabine                                                    Fulvestrant + Zoledronic acid
  Second line treatment            Tamoxifen                               Letrozole                               Letrozole                                                                   Capecitabine
  Third line treatment             Paclitaxel + Bevacizumab                Ciclofosfamide e Metotrexate            Did not receive                                                             Did not receive
  Immunihistochemical profile      RE/RP 100%, Her-2 negative, Ki 67 10%   RE/RP 100%, Her-2 negative, ki 67 60%   RE/RP 100%, Her-2 negative, ki 67 30%                                       RE/RP 100%, Her-2 inconclusive, ki 67 15%
  Gastric metastasis diagnosis     May 2005                                Mar 2013                                Jul 2012                                                                    May 2013
  Metastasis site                  Only gastric metastasis                 Lymph nodes, peritoneum                 Peritoneum, stomach, colon, abdominal lymph nodes                           Bones, lymph nodes and gastric metastasis
  Metastasis endoscopy results     Ulcerated lesion                        Diffuse Infiltration (linitis)          Infiltration and ulcerated lesion, stenosing in distal antrum and pylorus   Flat erosions
  Metastasis pathology results     RE/PR 100% Her-2 negative               RE/PR 100% Her-2 negative               RE/RP 100% Her-2 negative                                                   RE 95%, RP 45, HER-2 negative
  Local treatment for metastasis   Surgery                                 Radiotherapy                            None                                                                        Radiotherapy
  Gastrectomy                      Yes                                     No                                      No                                                                          No
  Date of death                    Jan 2013                                Nov 2014                                No                                                                          Mar 2014
  Meningeal infiltration           Yes                                     Yes                                     No                                                                          Yes

[^1]: Contributions: the authors contributed equally.

[^2]: Conflict of interest: the authors declare no potential conflict of interest.
